| U.S. Brand Names |
| Cantil® |
 |
| Generic Available |
|
No |
|
| Synonyms |
| Mepenzolate Bromide |
|
| Pharmacological Index |
|
Anticholinergic Agent; Antispasmodic Agent, Gastrointestinal |
|
| Use |
|
Management of peptic ulcer disease; inhibit salivation and excessive secretions in respiratory tract preoperatively |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Angle-closure glaucoma; acute hemorrhage; tachycardia; hypersensitivity to mepenzolate or any component; obstructive uropathy (ie, bladder neck obstruction due to prostatic hypertrophy); obstructive gastrointestinal disease (ie, pyloroduodenal stenosis, achalasia); paralytic ileus; intestinal atony of the debilitated or elderly patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis or toxic megacolon complicating ulcerative colitis; myasthenia gravis; allergic or idiosyncratic reactions of related compounds |
|
| Adverse Reactions |
|
>10%: Gastrointestinal: Constipation, xerostomia, dry throat Dermatologic: Dry skin Respiratory: Dry nose Miscellaneous: Decreased diaphoresis 1% to 10%: Gastrointestinal: Dysphagia |
|
| Usual Dosage |
|
Adults: Oral: 25-50 mg 4 times/day with meal and at bedtime |
|
| Dietary Considerations |
|
May be administered with meals |
|
| Mental Health: Effects on Mental Status |
|
May rarely cause confusion, amnesia, drowsiness, nervousness, or insomnia |
|
| Mental Health: Effects on Psychiatric Treatment |
|
Concurrent use with psychotropics may produce additive drowsiness or anticholinergic side effects (dry mouth) |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
>10% of patients experience dry mouth |
|
| Dosage Forms |
|
Tablet, as bromide: 25 mg |
|
|
Copyright © 2007 Drugs Area |
